Padagis Israel

Padagis Israel (Hebrew: פאדאגיס-ישראל) is an Israeli pharmaceutical company that markets prescription medicines, over-the-counter drugs and diagnostic products. According to its official website, the company represents leading international manufacturers — including Aspen, Grifols, GSK, Sandoz, Ascensia Diabetes Care, Pierre Fabre, Blistex, Perrigo, Advantice Health, Sakura Finetek, Dexcom Inc., Siemens Healthcare and Celltrion Healthcare — alongside products manufactured in its own facilities. Its customers include hospitals, health funds (kupot holim) and pharmacies across Israel's institutional, private and pharmacy-chain markets. The company traces its Israeli roots to 1961, when it was founded as Agis. In 2005 Agis was acquired by Perrigo Company PLC, the US-based OTC healthcare group. In 2021 the prescription pharmaceutical business that includes Padagis Israel was sold to Altaris Capital Partners, a healthcare-focused investment fund. Padagis Israel today employs 841 people in Israel, making it one of the largest employers in the Negev; more than 600 of its employees work at its generic drug development and manufacturing plant in Yeruham, while the rest are based in commercial and logistics units in the Shoham industrial park. Padagis Israel's prescription division markets locally manufactured medicines from the Yeruham plants and imports products from international companies such as Grifols, Celltrion, Norgine and Kyowa Kirin. Its therapeutic coverage spans nearly all areas of medicine, from blood products through oncology and gastroenterology to men's health, and the company states that it leads the dermatology field in Israel. Its stated vision is to improve the well-being of patients and consumers by supplying high-quality, competitively priced health products.

Padagis Israel's history in Israel begins in 1961, when the company was founded under the name Agis. Over the following decades Agis established itself as an Israeli pharmaceutical company, and in 2005 it was acquired by Perrigo Company PLC, a US-based over-the-counter healthcare group. Under Perrigo, the Israeli operation continued to develop and manufacture generic drugs, notably at its plant in Yeruham in the Negev, while also marketing and importing a broad range of prescription and OTC products. In 2021, Perrigo sold its prescription pharmaceutical business — of which Padagis Israel is a part — to Altaris Capital Partners, a healthcare-focused investment fund. The business was rebranded as Padagis, and the Israeli entity became Padagis Israel. Today the company employs 841 people in Israel, with more than 600 at the Yeruham generic drug development and manufacturing plant and the remainder in commercial and logistics units at the Shoham industrial park. It markets locally produced medicines as well as products from international partners such as Aspen, Grifols, GSK, Sandoz, Ascensia Diabetes Care, Pierre Fabre, Blistex, Perrigo, Advantice Health, Sakura Finetek, Dexcom Inc., Siemens Healthcare and Celltrion Healthcare, serving hospitals, health funds and pharmacies across Israel.

• 2021

  Perrigo's prescription pharmaceutical business, including Padagis Israel, sold to Altaris Capital Partners.

• 2005

  Agis acquired by Perrigo Company PLC.

• 1961

  Company founded in Israel as Agis.

Leading Israeli pharmaceutical company and one of the largest employers in the Negev, representing international manufacturers and supplying hospitals, health funds and pharmacies.

• Prescription medicines

• Over-the-counter drugs

• Diagnostic products

• Generic drugs

• Biosimilar medicines

• Blood products

• Oncology products

• Gastroenterology products

• Men's health products

• Dermatology products

• Continuous glucose monitors

• Medical equipment

• Consumer products

1. 1עמוד הבית - Padagispadagis.co.il
2. 2Padagis Israel - Wikidatawikidata.org